Ophthalmology Search
Ophthalmology Ophthalmology
primary%20open-angle%20glaucoma
PRIMARY OPEN-ANGLE GLAUCOMA
Primary open-angle glaucoma (POAG) is a chronic, progressive, usually bilateral disease of the eye with an insidious onset.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.
  1. Broan AM, Garcger CP, Sirbat D, et al. Comparison of two fixed beta-blocker-pilocarpine combinations. The Carteolol-Pilocarpine Study Group. Eur J Ophthalmol. 1997;7(4):351-356. Accessed 10 Feb 2012. PMID: 9457458
  2. Demailly P, Allaire C, Bron V, Trinquand C. Effectiveness and tolerance of beta blocker/pilocarpine combination eye drops in primary open-angle glaucoma and high intraocular pressure. J Glaucoma. 1995 Aug;4(4):235-241. Accessed 10 Feb 2012. PMID: 19920680
  3. South East Asia Interest Group. Asia Pacific glaucoma guidelines. 2nd ed. Sydney, Australia: SEAGIG; 2008
  4. Henderson P, Labbe T, Kass MA. Ocular hypertension. In: Yanoff M, Duker JS, Augsburger JJ, et al. Yanoff & Duker: Ophthalmology. 3rd ed. Maryland Heights, MO: Mosby, Inc; 2008
  5. National Collaborating Centre for Acute Care. Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension. http://www.nice.org.uk/nicemedia/live/12145/43887/43887.pdf.April. Apr 2009. Accessed 03 Feb 2012
  6. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Guidelines. Primary open-angle glaucoma. San Francisco, CA: American Academy of Ophthalmology. http://one.aao.org/summary-benchmark-detail/primary-openangle-glaucoma-suspect-summary-benchma. Oct 2013
  7. American Optometric Association Original Consensus Panel on Care of the Patient with Open-Angle Glaucoma. Optometric clinical practice guideline care of the patient with open-angle glaucoma. American Optometric Association. http://www.aoa.org/documents/CPG-9.pdf. 2010. Accessed 03 Feb 2012
  8. International Council of Ophthalmology. Primary open-angle glaucoma: initial evaluation. International Council of Ophthalmology. http://www.icoph.org/dynamic/attachments/resources/icopoaglaucomainev_2.pdf. 2010. Accessed 04 Feb 2012
  9. International Council of Ophthalmology. Primary open-angle glaucoma: follow-up evaluation. International Council of Ophthalmology. http://www.icoph.org/dynamic/attachments/resources/icopoaglaucomafu_2.pdf. 2010. Accessed 04 Feb 2012
  10. International Council of Ophthalmology. Primary open-angle glaucoma suspect: initial evaluation and follow-up. International Council of Ophthalmology. http://www.icoph.org/dynamic/attachments/resources/icopoagsuspect_2.pdf. 2010. Accessed 06 Feb 2012
  11. Jacobs DS. Open-angle glaucoma: epidemiology, clinical presentation, and diagnosis. UpToDate. http://www.uptodate.com/contents/open-angle-glaucoma-epidemiology-clinical-presentation-and-diagnosis. 15 Jun 2015.
  12. Jacobs DS. Open-angle glaucoma: treatment. UpToDate. http://www.uptodate.com/contents/open-angle-glaucoma-treatment. 07 Apr 2015.
  13. European Glaucoma Society (EGS). Terminology and guidelines for glaucoma. 4th ed. EGS. http://www.eugs.org/eng/EGS_guidelines4.asp. Jun 2014.
Editor's Recommendations
Most Read Articles
Beta-blockers may reduce mortality in patients with heart failure, renal dysfunction
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
New from USPSTF: Breast cancer risk-reduction recommendations
Elvira Manzano, 3 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
UTI risk not raised with SGLT-2is in real-world study
Pearl Toh, 4 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Lower HbA1c prolongs hypoglycaemia duration in type 2 diabetics
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.